×
About 53,918 results

ALLMedicine™ Small Cell Lung Cancer Center

Research & Reviews  16,839 results

Persistent dry cough
https://www.mdedge.com/lung-cancer-challenge-center/article/254800/lung-cancer/persistent-dry-cough

May 20th, 2022 - On the basis of the patient's presentation, history, and imaging results, the likely diagnosis is metastatic small cell lung cancer (SCLC). Most patients with SCLC present with hematogenous metastases; only about one third present with limited dis.

Non-Small Cell Lung Cancer (NSCLC)
https://emedicine.medscape.com/article/279960-overview

May 20th, 2022 - Practice Essentials Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. Patient...

Non-Small Cell Lung Cancer (NSCLC)
http://emedicine.medscape.com/article/279960-overview

May 20th, 2022 - Practice Essentials Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. Patient...

Non-Small Cell Lung Cancer (NSCLC)
https://emedicine.medscape.com/article/2241676-overview

May 20th, 2022 - Practice Essentials Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. Patient...

Non-Small Cell Lung Cancer (NSCLC) Clinical Presentation
http://emedicine.medscape.com/article/279960-clinical

May 20th, 2022 - History Lung cancer is often insidious, producing no symptoms until the disease is well advanced. In approximately 7-10% of cases, lung cancer is diagnosed in asymptomatic patients when a chest radiograph performed for other reasons reveals the di...

see more →

Guidelines  27 results

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628757
Current Oncology (Toronto, Ont.); Cheema PK, Banerji SO et. al.

Dec 14th, 2021 - In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatm...

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0058
Journal of the National Comprehensive Cancer Network : JN... Ganti AKP, Loo BW et. al.

Dec 14th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment...

Definition and assessment of high risk in patients considered for lobectomy for stage I...
https://doi.org/10.1016/j.jtcvs.2021.07.030
The Journal of Thoracic and Cardiovascular Surgery; Pennathur A, Brunelli A et. al.

Oct 31st, 2021 - Lobectomy is a standard treatment for stage I non-small cell lung cancer, but a significant proportion of patients are considered at high risk for complications, including mortality, after lobectomy and might not be candidates. Identifying who is ...

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0013
Journal of the National Comprehensive Cancer Network : JN... Ettinger DS, Wood DE et. al.

Mar 6th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targete...

Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHES...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177089
Chest Mazzone PJ, Gould MK et. al.

Apr 27th, 2020 - The risks from potential exposure to coronavirus disease 2019 (COVID-19), and resource reallocation that has occurred to combat the pandemic, have altered the balance of benefits and harms that informed current (pre-COVID-19) guideline recommendat...

see more →

Drugs  172 results see all →

Clinicaltrials.gov  1,515 results

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02133196

May 20th, 2022 - Background: Patients with metastatic non-small cell lung cancer (NSCLC) have few approved therapeutic options and those that exist are of transient benefit. Recent clinical experiences with experimental agents that release checkpoints on the host ...

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04826341

May 20th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02194738

May 20th, 2022 - PRIMARY OBJECTIVES: I. To centrally test resected non-small cell lung cancer (NSCLC) for genetic mutations to facilitate accrual to randomized adjuvant studies. II. To obtain clinically annotated tumor tissue and patient-matched non-malignant deox...

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unrese...
https://clinicaltrials.gov/ct2/show/NCT03833154

May 20th, 2022 - Patients who are to receive SoC SBRT as definitive treatment of Stage I/II lymph node-negative NSCLC and confirmed to meet all eligibility criteria will be randomized 1:1 to Durvalumab or placebo. The primary objective of main cohort is to assess ...

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT04077463

May 20th, 2022 - Lung cancer is one of the most common types of cancer and is also the most common cause of death from cancer. NSCLC accounts for 85 percent (%) to 90% of lung cancers. Lazertinib is an oral, highly potent, mutant-selective, and irreversible EGFR-t...

see more →

News  3,013 results

Persistent dry cough
https://www.mdedge.com/lung-cancer-challenge-center/article/254800/lung-cancer/persistent-dry-cough

May 20th, 2022 - On the basis of the patient's presentation, history, and imaging results, the likely diagnosis is metastatic small cell lung cancer (SCLC). Most patients with SCLC present with hematogenous metastases; only about one third present with limited dis.

Applicability of the USPSTF Lung Cancer Screening Guidelines in a Predominantly Black Veteran Population
https://www.mdedge.com/fedprac/article/254640/lung-cancer/applicability-uspstf-lung-cancer-screening-guidelines
Thomas N. Rusher, MD, Lekha Deere, MD et. al.

May 16th, 2022 - Lung cancer is the leading cause of cancer death in the United States. 1 The 2011 National Lung Screening Trial (NLST) demonstrated that low-dose computed tomography (LDCT) screening provided a 20% relative reduction in lung cancer–specific mortali.

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

Updates in Treatment of HER2 Mutant NSCLC
https://www.onclive.com/view/updates-in-treatment-of-her2-mutant-nsclc

May 5th, 2022 - Ben Levy, MD: Let’s shift gears to HER2 exon 20, which isn’t to be confused with EGFR exon 20. Not all HER2 is exon 20, but most are. Misako, do you want to walk us through this? We’ve got some very exciting data coming down the pike for these mut...

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/view/jdq443-demonstrates-early-efficacy-signals-in-kras-g12c-mutant-solid-tumors

May 2nd, 2022 - The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 (NCT04699188) trial presented at the 2022 AACR Annual Meeting....

see more →

Patient Education  1 results see all →